Meeder Asset Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Meeder Asset Management’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-92	Closed	-$7K	–	2698
2021 Q1	$7K	Buy	+92	New	+$9.56K	﹤0.01%	1756
2020 Q4	–	Sell	-942	Closed	-$82K	–	2275
2020 Q3	$82K	Buy	+942	New	+$107K	0.01%	837
2020 Q1	–	Sell	-123	Closed	-$8K	–	2576
2019 Q4	$8K	Buy	123 +104	+547%	+$6.31K	﹤0.01%	1650
2019 Q3	$2K	Buy	+19	New	+$1.79K	﹤0.01%	2003
2019 Q2	–	Sell	-28	Closed	-$3K	–	2169
2019 Q1	$3K	Sell	28 -31	-53%	-$2.16K	﹤0.01%	1514
2018 Q4	$3K	Buy	59 +48	+436%	+$3.65K	﹤0.01%	1534
2018 Q3	$1K	Sell	11 -1	-8%	-$116	﹤0.01%	1501
2018 Q2	$1.21K	Sell	12 -2	-14%	-$248	﹤0.01%	1465
2018 Q1	$2K	Sell	14 -21	-60%	-$2.3K	﹤0.01%	1403
2017 Q4	$3K	Buy	35 +30	+600%	+$4.03K	﹤0.01%	1450
2017 Q3	$1K	Sell	5 -19	-79%	-$3.57K	﹤0.01%	1574
2017 Q2	$4K	Hold	24	–	–	﹤0.01%	1282
2017 Q1	$4K	Buy	24 +14	+140%	+$1.71K	﹤0.01%	1191
2016 Q4	$1K	Buy	+10	New	+$1.4K	﹤0.01%	963

Other funds holding SYRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Meeder Asset Management's SYRS Position: Q2 2021 in Review

Meeder Asset Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2021, closing a stake of 92 shares — an estimated $7K sold.

Meeder Asset Management first reported a position in SYRS in Q4 2016 and held it in 14 quarters. The position peaked at $82K in Q3 2020. 100 funds tracked by Wall St. Rank hold SYRS as of Q2 2021.

Meeder Asset Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Meeder Asset Management sold 92 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $7K.
Meeder Asset Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 14 quarters.
Meeder Asset Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $82K in Q3 2020.
100 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on Meeder Asset Management's 13F filing for Q2 2021, filed 9 Aug 2021.